Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$479M |
| 2 |
Meta Platforms (Facebook)
META
|
+$465M |
| 3 |
State Street Consumer Discretionary Select Sector SPDR ETF
XLY
|
+$445M |
| 4 |
Kenvue
KVUE
|
+$434M |
| 5 |
Micron Technology
MU
|
+$431M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$3.24B |
| 2 |
Apple
AAPL
|
+$1.9B |
| 3 |
Microsoft
MSFT
|
+$1.56B |
| 4 |
PepsiCo
PEP
|
+$1.34B |
| 5 |
JPMorgan Chase
JPM
|
+$1.34B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.7% |
| 2 | Financials | 7.47% |
| 3 | Consumer Discretionary | 6.7% |
| 4 | Communication Services | 6.02% |
| 5 | Healthcare | 4.93% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
GRAL
1626
GRAIL Inc
GRAL
$3.05B
| $10.8M | ﹤0.01% |
125,658
+31,652
| +34% | +$2.73M |
|
1627
PUT
Molson Coors Class B
TAP
$7.85B
| $10.7M | ﹤0.01% |
230,000
-200,000
| -47% | -$9.23M |
|
1628
ITT
ITT
$19.4B
| $10.7M | ﹤0.01% |
61,781
-58,136
| -48% | -$10.4M |
|
1629
Commerce Bancshares
CBSH
$8.61B
| $10.7M | ﹤0.01% |
204,694
+62,085
| +44% | +$3.25M |
|
|
SNV
1630
DELISTED
Synovus
SNV
| $10.7M | ﹤0.01% |
214,046
-996,991
| -82% | -$47.9M |
|
1631
Spire
SR
$4.9B
| $10.7M | ﹤0.01% |
129,501
-7,521
| -5% | -$641K |
|
1632
Ameris Bancorp
ABCB
$6B
| $10.7M | ﹤0.01% |
143,629
+41,682
| +41% | +$3.1M |
|
1633
LXP Industrial Trust
LXP
$3.58B
| $10.7M | ﹤0.01% |
215,114
+7,291
| +4% | +$349K |
|
1634
IMAX
IMAX
$2.92B
| $10.7M | ﹤0.01% |
288,434
-94,795
| -25% | -$3.31M |
|
1635
PJT Partners
PJT
$4.57B
| $10.6M | ﹤0.01% |
63,613
+15,170
| +31% | +$2.59M |
|
1636
CALL
Hewlett Packard
HPE
$79.2B
| $10.6M | ﹤0.01% |
+442,700
| New | +$10.4M |
|
1637
CALL
Fortinet
FTNT
$121B
| $10.6M | ﹤0.01% |
133,900
+129,600
| +3,014% | +$10.7M |
|
|
CWAN
1638
DELISTED
Clearwater Analytics
CWAN
| $10.6M | ﹤0.01% |
438,639
-287,802
| -40% | -$5.76M |
|
1639
CALL
United Rentals
URI
$69.7B
| $10.5M | ﹤0.01% |
13,000
-1,200
| -8% | -$1.04M |
|
1640
British American Tobacco
BTI
$124B
| $10.5M | ﹤0.01% |
185,077
-62,691
| -25% | -$3.42M |
|
1641
PUT
BP
BP
$110B
| $10.4M | ﹤0.01% |
+300,000
| New | +$10.5M |
|
1642
Wolfspeed
WOLF
$1.64B
| $10.4M | ﹤0.01% |
598,407
-1,285,634
| -68% | -$29.5M |
|
1643
Ocular Therapeutix
OCUL
$2.22B
| $10.4M | ﹤0.01% |
857,649
+446,032
| +108% | +$5.42M |
|
1644
Liberty Energy
LBRT
$3.45B
| $10.4M | ﹤0.01% |
562,861
+275,972
| +96% | +$4.61M |
|
1645
Belden
BDC
$5.36B
| $10.4M | ﹤0.01% |
88,965
-4,533
| -5% | -$529K |
|
1646
PUT
Moderna
MRNA
$25.4B
| $10.4M | ﹤0.01% |
351,300
+45,000
| +15% | +$1.22M |
|
1647
Centrus Energy
LEU
$3.83B
| $10.4M | ﹤0.01% |
42,659
+18,463
| +76% | +$5.58M |
|
1648
Semtech
SMTC
$12.4B
| $10.3M | ﹤0.01% |
140,093
-362,069
| -72% | -$25.7M |
|
1649
Asbury Automotive
ABG
$3.78B
| $10.3M | ﹤0.01% |
44,378
+15,589
| +54% | +$3.69M |
|
1650
PUT
Okta
OKTA
$26.9B
| $10.3M | ﹤0.01% |
119,200
-150,000
| -56% | -$13.1M |
|
Similar funds
Barclays's Q4 2025 Portfolio in Review
As of Q4 2025, Barclays held 5,847 positions worth $417B, down 9.7% from $461B the previous quarter. Its ten largest holdings account for 35% of the portfolio.
Barclays withdrew a net $49.1B in Q4 2025, closing 641 positions and reducing 1,715 holdings. Its most notable exit was Verona Pharma, an estimated $149M position sold in full.
By sector, the portfolio is most concentrated in Technology at 20% of assets, down from 20% a quarter earlier, followed by Financials and Consumer Discretionary.
Against the trend, Barclays opened a new position in The Magnum Ice Cream Company N.V. worth $156M.
- Barclays's largest Q4 2025 buy was The Magnum Ice Cream Company N.V.: 9,862,859 shares worth $156M.
- Barclays added most to Gilead Sciences in Q4 2025, an estimated $479M increase.
- Barclays's biggest Q4 2025 reduction was NVIDIA, cutting an estimated $3.24B.
- Barclays fully exited Verona Pharma in Q4 2025, selling an estimated $149M.
- Barclays's ten largest holdings make up 35% of its $417B portfolio in Q4 2025.
- Barclays opened 403 new positions and closed 641 in Q4 2025.
- Barclays's portfolio value fell 9.7% quarter-over-quarter to $417B.
Based on Barclays's 13F filing for Q4 2025, filed 13 Feb 2026.